The global migraine drugs market size reached US$ 4.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2024-2032. More Info:- https://www.imarcgroup.com/migraine-drugs-market

1. Global Migraine Drugs
Market Research and
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved

2. About IMARC Group
International Market Analysis Research and Consulting Group is a leading adviser on management
strategy and market research worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their most critical challenges, and
transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods
are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting
results.

3. Report Highlight
and Description
According to the latest report by IMARC Group, titled "Migraine Drugs
Market: Global Industry Trends, Share, Size, Growth, Opportunity and
Forecast 2024-2032," the global migraine drugs market size reached US$ 4.2
Billion in 2023.
Migraine drugs refer to medications that are used to reduce the severity of
migraines and prevent future attacks. A migraine is a severe, neurological
disease with a debilitating headache, characterized by an intense throbbing or
pulsing in one area of the head.
It is accompanied by sensitivity to light, sound and smell, visual disturbances
such as auras, and nausea or vomiting. Migraine drugs do not cure migraines;
instead, they treat or relieve these symptoms. There are certain blood pressure
medications, as well as some antidepressants, anti-seizure drugs and herbals
that are used to reduce the frequency of migraines.
Request for a PDF sample of this report:
https://www.imarcgroup.com/migraine -drugs-market/requestsample

4. Report Description
Global Migraine Drugs Market Trends:
According to the Migraine Trust, migraine is the third most common disease globally, with more than 10% of
people getting affected by the condition worldwide. This represents the primary factor that has increased the
demand for migraine drugs across the globe. Apart from this, the rising healthcare expenditure and improving
reimbursement policies for migraine medications are also acting as growth-inducing factors.
Besides this, healthcare providers have made significant advancements in the diagnosis and treatment of
migraine. A more advanced treatment modality with mechanism-based therapies, including supraorbital
transcutaneous stimulation (STS) and transcranial magnetic stimulation, has been introduced as a preventive
therapy for migraine. Additionally, there are many other drugs with novel mechanisms of action or new therapeutic
targets, which are in different development stages.
View Report TOC, Figures and Tables: https://www.imarcgroup.com/migraine-drugs-market

5. Report
Segmentation
Breakup by Treatment Type:
• Abortive Treatment
• Preventive Treatment
Breakup by Drug Type:
• Triptans
• Ergot Alkaloids
• NSAIDs
• Acetylcholine Inhibitors/ Neurotoxins
• Ditans
• CGRP mAbs
• Others
Breakup by Route of Administration:
• Oral

6. Report
Segmentation
• Injectable
• Others
Breakup by Distribution Channel:
• Hospital-Based Pharmacies
• Retail Pharmacies
• Others
Breakup by Region:
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

7. Competitive
Landscape with
Key Players
• Abbott Laboratories
• Allergan Plc (Abbvie Inc.)
• Amgen Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc. (formerly Valeant
Pharmaceuticals)
• Eisai Co. Ltd.
• Eli Lilly and Company
• Endo International Plc
• GlaxoSmithKline Plc
• Johnson & Johnson
• Merck & Co.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Limited.

8. Key Questions
Answered in
the Report
How has the global migraine drugs market
performed so far and how will it perform in the
coming years?
What has been the impact of COVID-19 on the
global migraine drugs market?
What are the key regional markets?
What is the breakup of the market based on the
treatment type?
What is the breakup of the market based on the
drug type?
What is the breakup of the market based on the
route of administration?
What is the breakup of the market based on the
distribution channel?

9. Key Questions
Answered in
the Report
What are the various stages in the value chain of the
industry?
What are the key driving factors and challenges in the
industry?
What is the structure of the global migraine drugs market and
who are the key players?
What is the degree of competition in the industry?

10. Table of
Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Migraine Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Treatment Type
6.1 Abortive Treatment
6.1.1 Market Trends
6.1.2 Mark et Forecast
6.2 Preventive Treatment
6.2.1 Mark et Trends
6.2.2 Mark et Forecast
7 Market Breakup by Drug Type
7.1 Triptans
7.1.1 Mark et Trends
7.1.2 Mark et Forecast

11. Table of
Contents
7.2 Ergot Alk aloids
7.2.1 Mark et Trends
7.2.2 Mark et Forecast
7.3 NSAIDs
7.3.1 Mark et Trends
7.3.2 Mark et Forecast
7.4 Acetylcholine Inhibitors/ Neurotoxins
7.4.1 Mark et Trends
7.4.2 Mark et Forecast
7.5 Ditans
7.5.1 Mark et Trends
7.5.2 Mark et Forecast
7.6 CGRP mAbs
7.6.1 Mark et Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Mark et Trends
7.7.2 Mark et Forecast
8 Market Breakup by Route of Administration
8.1 Oral
8.1.1 Mark et Trends
8.1.2 Mark et Forecast
8.2 Injectable
8.2.1 Market Trends
8.2.2 Mark et Forecast
8.3 Others
8.3.1 Mark et Trends
8.3.2 Mark et Forecast
For more information, visit :
https://www.imarcgroup.com/migraine -drugs-market/toc

12. Disclaimer
© 2023 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the
name of International Market Analysis Research and Consulting (IMARC). No part of this
publication may be reproduced, repackaged, redistributed or resold in whole or in any part.
The publication may also not be used in any form or by and means graphic electronic or
mechanical, including photocopying, recording, taping or by information storage or retrieval,
or by any other form, without the express consent of International Market Analysis Research
and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and
opinion have been based on information and sources believed to be accurate and reliable at
the time of publishing. International Market Analysis Research and Consulting makes no
representation of warranty of any kind as to the accuracy or completeness of any Information
provided. IMARC accepts no liability whatsoever for any loss or damage resulting from
opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of
International Market Analysis Research and Consulting. All other trademarks used in this
publication are registered trademarks of their respective companies.

13. Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com